Syneos Health to Present at the 39th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Syneos Health (Nasdaq:SYNH) will have CEO Alistair Macdonald present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 8:20 a.m. EST. This event will provide insights into the company's integrated biopharmaceutical solutions. Investors can access a live webcast, presentation materials, and an archived audio replay via the Company’s Investor Relations website. Syneos Health is focused on enhancing customer performance by leveraging around 24,000 clinical and commercial experts across over 110 countries.
Positive
- None.
Negative
- None.
News Market Reaction – SYNH
In the trading session that priced this news, SYNH gained 1.43%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 8:20 a.m. EST.
A live webcast of the event, along with a link to the presentation materials and archived audio replay of the presentation, will be available on the Company’s Investor Relations website at investor.syneoshealth.com.
About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.
Contacts
| Investor Relations: | Press/Media: | |
| Ronnie Speight | Danielle DeForge | |
| Senior Vice President, Investor Relations | Vice President, External Communications | |
| +1 919 745 2745 | +1 202 210 5992 | |
| Investor.Relations@syneoshealth.com | danielle.deforge@syneoshealth.com |